Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans

The Lancet

Volumn 335, Issue 8689, 1990, Pages 555-557

  Fiessinger, J N ^a   Schafer M ^b  

^a BICHAT HOSPITAL   (France)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ILOPROST;

ANALGESIA; ARTICLE; BUERGER DISEASE; CLINICAL TRIAL; CONTROLLED STUDY; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEG ULCER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULCER HEALING;

ADOLESCENT; ADULT; AMPUTATION; ANTI-ARRHYTHMIA AGENTS; ARM; ASPIRIN; COMPARATIVE STUDY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; EPOPROSTENOL; FOLLOW-UP STUDIES; HUMAN; ILOPROST; ISCHEMIA; LEG; MIDDLE AGE; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; THROMBOANGIITIS OBLITERANS;

EID: 0025271194     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/0140-6736(90)90346-7     Document Type: Article

References (14)

1. Thromboangiitis obliterans: an autoimmune disorder?
2. Thromboangiitis obliterans and arteriosclerosis obliterans. Clinical and prognostic differences
3. A rational basis for management of patients with the Buerger syndrome
4. Natural history of Buerger's disease
5. Beurger's disease in the modem era
6. 1 (cyclodextrin clathrate) in patients with ischemic ulcer of the extremities
7. 1 in a woman with thromboangiitis obliterans
8. Prostacyclin for ischemic ulcers in peripheral arterial disease. A random assignment, placebo controlled study
9. 1 in severe peripheral vascular disease
10. Successful therapy of advanced arteriosclerosis obliterans with prostacyclin
11. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial
12. 2 in peripheral arterial ischemia
13. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructable peripheral arterial occlusive disease
14. Thromboangiitis obliterans: Diagnose und Therapie im licht neuer immunologischer Befunde